SynthesisJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Comparing GLP-1 agonists versus other weight loss interventions on risk of atrial fibrillation recurrence after catheter ablation: a meta-analysis.
Synthesis in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundObesity often co-exists with Atrial Fibrillation (AF) and poses challenges to ablation success. Whether glucagon-like peptide-1 (GLP-1) agonists have a role and how they compare to other weight loss interventions in preventing AF recurrence after catheter ablation remains unclear.
methodsWe performed meta-analysis and included prior interventional and observational studies that investigated weight loss-related interventions on AF recurrence post-ablation. Included were weight loss interventions that entailed perioperative use of GLP-1 agonists (4 studies), non-pharmacological interventions such as lifestyle/ risk factors modifications (8 studies), and bariatric surgery (1 study). Primary outcome was recurrence of clinical AF or a requirement for further rhythm control post-ablation.
resultsTwo randomized-control trials and 11 cohorts were included (n = 5,415). Overall, weight loss interventions were associated with significant reduction in AF recurrence post-ablation (RR = 0.63 [95% CI: 0.46—0.87]). Bariatric surgery was associated with reduced risk of AF recurrence (RR = 0.31 [0.13 to 0.75]), while GLP-1 agonists and lifestyle /risk factors modifications showed trends towards protection with borderline statistical significance (RR = 0.64 [95% CI 0.36 to 1.14]). However, only 1 study investigated bariatric surgery which should be interpreted with caution. Importantly, meta-regression showed that for each 1% absolute decrease in body weight achieved, there was 6.3% relative-risk reduction in AF recurrence (RR = 0.94 [0.90—0.98]), regardless of weight loss intervention subtype. Sustained continuation of weight loss post-ablation was a determining factor of lower recurrence (P = 0.03).
conclusionsPeri-operative weight loss interventions in obesity patients significantly reduced AF recurrence post-ablation, in a dose–response manner and irrespective of choice of intervention strategy. Sustained continuation of weight loss post-ablation is a key determinant of success.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.